Gene transfer to mouse heart and skeletal muscles using a minicircle expressing human vascular endothelial growth factor

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 1, 2009, Pages 18-23

  Stenler, Sofia ^a   Andersson, Agneta ^a   Simonson, Oscar E ^a   Lundin, Karin E ^a   Chen, Zhi Ying ^b   Kay, Mark A ^b   Smith, C I Edvard ^a   Sylvén, Christer ^a   Blomberg, Pontus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efficacy; Gene therapy; In vitro; In vivo; Minicircle; Plasmid gene expression

Indexed keywords

MINICIRCLE DNA; VASCULOTROPIN; DNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE CASSETTE; GENE EXPRESSION; GENE TRANSFER; HEART MUSCLE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SKELETAL MUSCLE; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; GENE THERAPY; GENE VECTOR; METABOLISM; NUCLEOTIDE SEQUENCE; VASCULARIZATION;

ANIMALS; BASE SEQUENCE; DNA; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYOCARDIUM; PLASMIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67651102609     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318194234e     Document Type: Article

References (21)

1. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther. 2007;15:1233-1247. (Pubitemid 46965318)
2. Chen ZY, He CY, Meuse L, et al. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther. 2004; 11:856-864. (Pubitemid 38714589)
3. Darquet AM, Cameron B, Wils P, et al. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 1997;4:1341-1349. (Pubitemid 28004593)
4. Bigger BW, Tolmachov O, Collombet JM, et al. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem. 2001;276: 2223018-2223027. (Pubitemid 37410994)
5. Chen ZY, He CY, Ehrhardt A, et al. Minicircle DNA vectors devoid of bacterial DNA results in persistent and high-level transgene expression in vivo. Mol Ther. 2003;8:495-500. (Pubitemid 37161471)
6. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNAvector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther. 2005;16:126-131.
7. Gal D, Weir L, Leclerc G, et al. Direct myocardial transfection on two animal models. Lab Invest. 1993;68:18-25.
8. Tannous BA, Kim DE, Fernandez JL, et al. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther. 2004;11:435-443.
9. Ge R, Svahn MG, Simonson OE, et al. Sequence-specific inhibition of RNA polymerase III-dependent transcription using Zorro locked nucleic acid (LNA). J Gene Med. 2008;10:101-109.
10. Liu F, Shollenberger LM, Huang L. Non-immunostimulatory nonviral vectors. FASEB J. 2004;18:1779-1781.
11. Food and Drug Administration. Guidance for Human Somatic Cell Therapy and Gene Therapy. Rockville, MD; 1998.
12. European Medicine Agency. Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products. London, United Kingdom; 2001. CPMP/BWP/3088/99.
13. Riu E, Chen ZY, Xu H, et al. Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther. 2007;15:1348-1355. (Pubitemid 46965331)
14. Wu J, Xiao X, Zhao P, et al. Minicircle-IFNg induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res. 2006;12:4702-4713. (Pubitemid 44297824)
15. Springer ML, Chen AS, Kraft PE, et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. 1998;2:549-558.
16. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 2000;102:898-901. (Pubitemid 30671507)
17. Chang CW, Christensen LV, Lee M, et al. Efficient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy. J Control Release. 2008;125:155-163. (Pubitemid 50008037)
18. Gyöngyö si M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation. 2005;112(Suppl 9):I157-I165.
19. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164: 944-953. (Pubitemid 30043721)
20. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164:1617-1624. (Pubitemid 30067282)
21. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol. 2008;26:549-551. (Pubitemid 351668040)